T1	condition 46 55	bone loss
T2	intervention 92 107	zoledronic acid
T4	control 540 547	placebo
T5	eligibility 59 77	premenopausal wome
T6	intervention-participants 594 604	Thirty-one
T7	control-participants 647 658	thirty-four
T11	iv-cont-mean 1116 1120	2.2%
T12	cv-cont-mean 1125 1129	7.3%
T13	iv-cont-mean 932 936	2.9%
T14	cv-cont-mean 981 985	7.1%
T3	outcome 899 922	BMD at the lumbar spine
T8	outcome 1137 1160	BMD at the lumbar spine
T9	outcome 1070 1078	60-month
T10	outcome 888 897	24â€¯months
T15	outcome 1385 1429	BMD-values at the femoral neck and total hip
